


# Cost-effectiveness of immediate HCV Rx in early disease analyzed

February 18 2015

---



Electron micrograph of hepatitis virus. Source: US Centers for Disease Control and Prevention

(HealthDay)—For patients with hepatitis C virus (HCV), immediate treatment seems to be cost-effective in those with moderate and advanced fibrosis, and can be cost-effective in patients with no or minimal fibrosis, according to a study published online Feb. 11 in *Hepatology*.

Andrew J. Leidner, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues examined the cost-effectiveness of new treatments for HCV, with a focus on patients in the early stages of liver disease. A state-transition model was developed to calculate costs incurred and quality-adjusted life-years (QALYs) gained by following HCV [treatment](#). Incremental cost-effectiveness ratios for

treatment were computed at different stages of liver disease versus delaying treatment until the subsequent [liver disease](#) stage. Potential benefits linked to reduced non-liver-related mortality or preventing HCV transmission were not included in analyses.

The researchers found that the best case scenario represented a patient aged 55 years with HCV genotype 1 infection for whom the treatment cost was \$100,000 and treatment effectiveness was 90 percent. The cost-effectiveness of immediately initiating treatment at Metavir stage F2 (moderate [liver fibrosis](#)) versus delaying treatment until F3 was \$37,300 per QALY. The threshold of treatment costs that yielded cost-effectiveness ratios of \$50,000/QALY and \$100,000/QALY were \$22,200 and \$42,400, respectively, for patients immediately treated at F0 versus delaying treatment until F1.

"Immediate treatment of HCV-infected patients with moderate and advanced fibrosis appears to be cost-effective," the authors write.

"Immediate treatment of [patients](#) with minimal or no fibrosis can be cost-effective as well, particularly when lower treatment costs are assumed."

The study was partially funded by pharmaceutical companies.

**More information:** [Abstract](#)  
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: Cost-effectiveness of immediate HCV Rx in early disease analyzed (2015, February 18) retrieved 27 April 2024 from <https://medicalxpress.com/news/2015-02-cost-effectiveness-hcv-rx-early-disease.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private
-----------------------------------------------------------------------------------------------

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.